Latest Period
Q1 2026
Security Snapshot
Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX) Institutional Ownership
CUSIP: 67080M103
13F Institutional Holders and Ownership History from Q3 2020 to Q1 2026
Institutions Reporting
194
Shares (Excl. Options)
117,027,314
Price
$15.50
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- NRIX on Nasdaq
- Shares outstanding
- 103,174,603
- Price per share
- $15.96
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 117,027,314
- Total reported value
- $1,813,892,353
- % of total 13F portfolios
- 0%
- Share change
- +2,995,743
- Value change
- +$39,578,803
- Number of holders
- 194
- Price from insider filings
- $15.96
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- NRIX - Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 67080M103.
- 194 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 182 to 194 between Q4 2025 and Q1 2026.
- Reported value moved from $2,151,627,911 to $1,813,892,353.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 194 institutions filings for Q1 2026.
Security key
67080M103
Latest holder period
Q1 2026
13F holders
194
13D/G owners
8
CIK / CUSIP context first
Open Q1 2026 holders
NRIX full holder history
Nurix Therapeutics, Inc. SEC filings
Nurix Therapeutics, Inc. company facts
Nurix Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 67080M103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
NRIX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 9.9% | $165,792,867 | 10,696,314 | Redmile Group, LLC | 20 Apr 2026 | |||
| BAKER BROS. ADVISORS LP | 7.2% | $138,364,566 | 7,527,996 | Baker Bros. Advisors LP | 31 Dec 2025 | |||
| Vestal Point Capital, LP | 6.3% | $100,815,000 | 6,500,000 | Vestal Point Capital, LP | 31 Mar 2026 | |||
| Deep Track Capital, LP | 6.2% | -15% | $98,414,734 | +$13,109,734 | 6,345,244 | +15% | Deep Track Capital, LP | 31 Mar 2026 |
| BlackRock, Inc. | 8.2% | $72,644,381 | 6,284,116 | BlackRock, Inc. | 31 Mar 2025 | |||
| FMR LLC | 5.4% | +32% | $85,945,115 | +$21,424,444 | 5,541,271 | +33% | FMR LLC | 31 Mar 2026 |
| Commodore Capital LP | 4.9% | -4% | $34,927,708 | -$646,292 | 3,780,055 | -1.8% | Commodore Capital LP | 30 Sep 2025 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.2% | $36,861,858 | 3,188,742 | Wellington Management Group LLP | 31 Mar 2025 |
As of 31 Mar 2026, 194 institutional investors reported holding 117,027,314 shares of Nurix Therapeutics, Inc. - Common Stock, par value $0.001 per share (NRIX). This represents 113% of the company’s total 103,174,603 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
87%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8.7% | 8,925,642 | +0.57% | 0% | $138,347,454 |
| Redmile Group, LLC | 7.5% | 7,732,808 | -4.5% | 7.9% | $119,858,524 |
| Vestal Point Capital, LP | 6.3% | 6,500,000 | +39% | 2.8% | $100,750,000 |
| Deep Track Capital, LP | 6.2% | 6,345,244 | -9.8% | 2% | $98,351,282 |
| FMR LLC | 5.4% | 5,541,271 | +31% | 0% | $85,889,703 |
| STATE STREET CORP | 5% | 5,141,195 | +44% | 0% | $79,688,523 |
| MORGAN STANLEY | 4.8% | 4,931,998 | +1% | 0% | $76,445,982 |
| BAKER BROS. ADVISORS LP | 4.5% | 4,658,556 | 0% | 0.41% | $72,207,618 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 4,427,112 | 0% | 0% | $68,620,236 |
| GENERAL ATLANTIC, L.P. | 4% | 4,101,865 | -16% | 3% | $63,578,908 |
| PERCEPTIVE ADVISORS LLC | 3.6% | 3,710,877 | +4.4% | 1.1% | $57,518,594 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.2% | 3,290,233 | +1.3% | 0.01% | $50,999,000 |
| Pictet Asset Management Holding SA | 2.6% | 2,726,138 | -21% | 0.04% | $42,255,139 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.4% | 2,520,229 | +5.7% | 0% | $39,070,487 |
| Rubric Capital Management LP | 2.4% | 2,473,885 | 0% | 0.47% | $38,345,218 |
| DEUTSCHE BANK AG\ | 2.2% | 2,295,024 | -7.7% | 0.01% | $35,572,872 |
| Commodore Capital LP | 2.2% | 2,275,000 | 0% | 2% | $35,262,500 |
| BRAIDWELL LP | 1.7% | 1,750,766 | -20% | 0.91% | $27,136,873 |
| Trails Edge Capital Partners, LP | 1.7% | 1,743,220 | 0% | 6.4% | $27,019,910 |
| ARK Investment Management LLC | 1.7% | 1,721,135 | +7.4% | 0.21% | $26,677,596 |
| Longaeva Partners L.P. | 1.4% | 1,490,202 | +61% | 1.1% | $23,098,131 |
| CITADEL ADVISORS LLC | 1.3% | 1,343,700 | +17% | 0.01% | $20,827,350 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,318,659 | +22% | 0% | $20,439,215 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.3% | 1,297,893 | 0% | 0.33% | $20,117,342 |
| Kynam Capital Management, LP | 1.2% | 1,194,757 | -39% | 1.2% | $18,518,734 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
23
Latest
Q1 2026
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 117,027,314 | $1,813,892,353 | +$39,578,803 | $15.50 | 194 |
| 2025 Q4 | 113,423,406 | $2,151,627,911 | +$525,564,750 | $18.97 | 182 |
| 2025 Q3 | 84,776,704 | $783,330,709 | -$36,480,592 | $9.24 | 171 |
| 2025 Q2 | 88,319,847 | $1,005,944,844 | +$40,932,248 | $11.39 | 161 |
| 2025 Q1 | 84,604,598 | $1,005,122,777 | +$28,667,924 | $11.88 | 168 |
| 2024 Q4 | 81,104,522 | $1,528,053,172 | +$225,677,197 | $18.84 | 173 |
| 2024 Q3 | 67,877,304 | $1,525,459,447 | +$59,100,303 | $22.47 | 170 |
| 2024 Q2 | 64,996,165 | $1,356,466,249 | +$340,051,233 | $20.87 | 172 |
| 2024 Q1 | 49,045,600 | $720,957,554 | +$50,639,301 | $14.70 | 138 |
| 2023 Q4 | 46,078,653 | $475,525,962 | +$17,732,104 | $10.32 | 127 |
| 2023 Q3 | 44,845,094 | $352,482,854 | +$8,466,362 | $7.86 | 129 |
| 2023 Q2 | 43,637,466 | $435,668,849 | +$11,852,256 | $9.99 | 124 |
| 2023 Q1 | 42,478,076 | $376,567,538 | -$3,101,624 | $8.88 | 121 |
| 2022 Q4 | 42,696,157 | $468,798,220 | +$2,144,188 | $10.98 | 119 |
| 2022 Q3 | 43,069,388 | $561,182,776 | -$38,324,545 | $13.03 | 114 |
| 2022 Q2 | 44,940,935 | $567,552,048 | +$55,435,115 | $12.67 | 100 |
| 2022 Q1 | 40,367,078 | $565,503,716 | -$19,332,926 | $14.01 | 111 |
| 2021 Q4 | 40,421,865 | $1,170,057,078 | +$25,875,537 | $28.95 | 121 |
| 2021 Q3 | 39,378,816 | $1,180,362,633 | -$11,970,711 | $29.96 | 110 |
| 2021 Q2 | 39,520,770 | $1,048,795,893 | -$66,662,023 | $26.53 | 103 |
| 2021 Q1 | 41,346,108 | $1,285,407,277 | +$254,357,641 | $31.09 | 99 |
| 2020 Q4 | 33,136,833 | $1,089,462,176 | +$26,868,033 | $32.88 | 67 |
| 2020 Q3 | 31,854,383 | $1,111,189,598 | +$1,111,189,598 | $34.91 | 64 |